

26. (Amended) The method of Claim 25, wherein said antibody is a humanized antibody.

27. (Amended) The method of Claim 26, wherein said antibody is the HuZAF antibody.,

Add the following new claims.

--33. (New) The method according to Claim 25, wherein said antibody is an anti-interleukin 12 antibody.

34. (New) The method according to Claim 33, wherein said antibody is in an amount effective to block the effect of interleukin 12.

35. (New) The method according to Claim 33, wherein said anti-interleukin 12 antibody is a monoclonal antibody.

36. (New) The method according to Claim 35, wherein said monoclonal antibody has a binding affinity of at least 10^8 M.

37. (New) The method according to Claim 35, wherein said monoclonal antibody is a chimeric monoclonal antibody or a humanized monoclonal antibody.

38. (New) The method according to Claim 37, wherein said monoclonal antibody is 5F2, 16F2, 16 G2, or 20E11 in a chimeric or humanized form.

39. (New) The method according to Claim 33, wherein said pharmaceutical formulation is administered to a patient orally, topically, subcutaneously, intramuscularly, or intravascularly.

40. (New) The method according to Claim 33, wherein said anti-interleukin 12 antibody is administered in a dose of 0.01-100 mg/kg body weight.

41. (New) The method according to Claim 40, wherein said anti-interleukin 12 antibody is administered in a dose of 0.1-10 mg/kg body weight.

42. (New) The method according to Claim 33, wherein said treatment reduces PASI by at least 50%.

43. (New) A method of treating a patient suffering from psoriasis comprising the step of administering to a patient a pharmaceutical formulation comprising an interleukin 12 receptor or its binding subunit that binds to interleukin 12.

44. (New) The method according to Claim 43, wherein said interleukin 12 receptor or its binding subunit is recombinantly linked to the Fc region of a human immunoglobulin.--

THE REMARKS

The Amendment

Claim 33 is supported by Claim 25 as filed.

Claim 34 is supported by page 14, lines 28-30.

Claim 35 is supported by page 14, lines 31-32.

Claim 36 is supported by page 15, lines 12-13.

Claim 37 is supported at page 14, line 30 through page 15, line 2.

Claim 38 is supported by page 15, lines 26-27.

Claim 39 is supported by page 14, lines 13-14.

Claims 40-41 are supported by page 16, lines 23-24.

Claim 42 is supported by page 17, lines 5-7.

Claims 43-44 are supported by page 15, lines 33-35.

No new matter is added to any of the above amendment. The Examiner is requested to enter the amendments.